Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep 24;79(1):146–155. doi: 10.1038/sj.bjc.6690024

Controversies in the management of advanced prostate cancer

C J Tyrrell 1
PMCID: PMC2362166  PMID: 10408706

Abstract

For advanced prostate cancer, the main hormone treatment against which other treatments are assessed is surgical castration. It is simple, safe and effective, however it is not acceptable to all patients. Medical castration by means of luteinizing hormone-releasing hormone (LH-RH) analogues such as goserelin acetate provides an alternative to surgical castration. Diethylstilboestrol, previously the only non-surgical alternative to orchidectomy, is no longer routinely used. Castration reduces serum testosterone by around 90%, but does not affect androgen biosynthesis in the adrenal glands. Addition of an anti-androgen to medical or surgical castration blocks the effect of remaining testosterone on prostate cells and is termed combined androgen blockade (CAB). CAB has now been compared with castration alone (medical and surgical) in numerous clinical trials. Some trials show advantage of CAB over castration, whereas others report no significant difference. The author favours the view that CAB has an advantage over castration. No study has reported that CAB is less effective than castration. Of the anti-androgens which are available for use in CAB, bicalutamide may be associated with a lower incidence of side-effects compared with the other non-steroidal anti-androgens and, in common with nilutamide, has the advantage of once-daily dosing. Only one study has compared anti-androgens within CAB: bicalutamide plus LH-RH analogue and flutamide plus LH-RH analogue. At 160-week follow-up, the groups were equivalent in terms of survival and time to progression. However, bicalutamide caused significantly less diarrhoea than flutamide. Withdrawal and intermittent therapy with anti-androgens extend the range of treatment options. © 1999 Cancer Research Campaign

Keywords: hormonal therapy, advanced prostate cancer, combined androgen blockade, luteinizing hormone-releasing hormone analogues, surgical castration, anti-androgens

Full Text

The Full Text of this article is available as a PDF (64.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alivizatos G., Oosterhof G. O. Update of hormonal treatment in cancer of the prostate. Anticancer Drugs. 1993 Jun;4(3):301–309. doi: 10.1097/00001813-199306000-00002. [DOI] [PubMed] [Google Scholar]
  2. Bales G. T., Chodak G. W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996 Jan;47(1A):38–53. doi: 10.1016/s0090-4295(96)80007-0. [DOI] [PubMed] [Google Scholar]
  3. Bamberger M. H., Lowe F. C. Ketoconazole in initial management and treatment of metastatic prostate cancer to spine. Urology. 1988 Oct;32(4):301–303. doi: 10.1016/0090-4295(88)90230-0. [DOI] [PubMed] [Google Scholar]
  4. Barradell L. B., Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging. 1994 Jul;5(1):59–80. doi: 10.2165/00002512-199405010-00006. [DOI] [PubMed] [Google Scholar]
  5. Bertagna C., De Géry A., Hucher M., François J. P., Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol. 1994 Apr;73(4):396–402. doi: 10.1111/j.1464-410x.1994.tb07603.x. [DOI] [PubMed] [Google Scholar]
  6. Boccardo F., Decensi A. U., Guarneri D., Martorana G., Fioretto L., Mini E., Macaluso M. P., Giuliani L., Santi L., Periti P. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study. Cancer Detect Prev. 1991;15(6):501–503. [PubMed] [Google Scholar]
  7. Boccardo F., Decensi A., Guarneri D., Rubagotti A., Oneto F., Martorana G., Giuliani L., Delli Ponti U., Petracco S., Cortellini P. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). Eur Urol. 1990;18 (Suppl 3):48–53. doi: 10.1159/000463981. [DOI] [PubMed] [Google Scholar]
  8. Boccardo F., Pace M., Rubagotti A., Guarneri D., Decensi A., Oneto F., Martorana G., Giuliani L., Selvaggi F., Battaglia M. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer. 1993;29A(8):1088–1093. doi: 10.1016/s0959-8049(05)80293-x. [DOI] [PubMed] [Google Scholar]
  9. Boccon-Gibod L., Laudat M. H., Dugue M. A., Steg A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol. 1986;12(6):400–402. doi: 10.1159/000472667. [DOI] [PubMed] [Google Scholar]
  10. Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol. 1979;5(5):303–306. doi: 10.1159/000473139. [DOI] [PubMed] [Google Scholar]
  11. Brewster S. F., Gillatt D. A. Advanced prostate cancer: what's new in hormonal manipulation? 1993 May 19-Jun 1Br J Hosp Med. 49(10):710-1, 714-5. [PubMed] [Google Scholar]
  12. Brogden R. N., Clissold S. P. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs. 1989 Aug;38(2):185–203. doi: 10.2165/00003495-198938020-00003. [DOI] [PubMed] [Google Scholar]
  13. Brogden R. N., Faulds D. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Apr;6(4):324–343. doi: 10.2165/00002512-199506040-00007. [DOI] [PubMed] [Google Scholar]
  14. Bruchovsky N., Goldenberg S. L., Akakura K., Rennie P. S. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer. 1993 Sep 1;72(5):1685–1691. doi: 10.1002/1097-0142(19930901)72:5<1685::aid-cncr2820720532>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  15. Béland G., Elhilali M., Fradet Y., Laroche B., Ramsey E. W., Trachtenberg J., Venner P. M., Tewari H. D. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 1990 Sep 1;66(5 Suppl):1074–1079. doi: 10.1002/cncr.1990.66.s5.1074. [DOI] [PubMed] [Google Scholar]
  16. Carlström K., Stege R., Henriksson P., Grande M., Gunnarsson P. O., Pousette A. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate. 1997 May 15;31(3):193–197. doi: 10.1002/(sici)1097-0045(19970515)31:3<193::aid-pros8>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  17. Cassileth B. R., Soloway M. S., Vogelzang N. J., Chou J. M., Schellhammer P. D., Seidmon E. J., Kennealey G. T. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res. 1992 Oct;1(5):323–329. doi: 10.1007/BF00434946. [DOI] [PubMed] [Google Scholar]
  18. Cassileth B. R., Soloway M. S., Vogelzang N. J., Schellhammer P. S., Seidmon E. J., Hait H. I., Kennealey G. T. Patients' choice of treatment in stage D prostate cancer. Urology. 1989 May;33(5 Suppl):57–62. doi: 10.1016/0090-4295(89)90108-8. [DOI] [PubMed] [Google Scholar]
  19. Catalona W. J. Management of cancer of the prostate. N Engl J Med. 1994 Oct 13;331(15):996–1004. doi: 10.1056/NEJM199410133311507. [DOI] [PubMed] [Google Scholar]
  20. Chang A., Yeap B., Davis T., Blum R., Hahn R., Khanna O., Fisher H., Rosenthal J., Witte R., Schinella R. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol. 1996 Aug;14(8):2250–2257. doi: 10.1200/JCO.1996.14.8.2250. [DOI] [PubMed] [Google Scholar]
  21. Cockshott I. D., Cooper K. J., Sweetmore D. S., Blacklock N. J., Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol. 1990;18 (Suppl 3):10–17. doi: 10.1159/000463972. [DOI] [PubMed] [Google Scholar]
  22. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A., Goodman P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17;321(7):419–424. doi: 10.1056/NEJM198908173210702. [DOI] [PubMed] [Google Scholar]
  23. Crawford E. D., Hussain M., DeAntoni E. P., Thompson I. M., Eisenberger M. A., Blumenstein B., Coltman C. A., Jr Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol. 1995 Jan-Feb;11(1):60–64. doi: 10.1002/ssu.2980110109. [DOI] [PubMed] [Google Scholar]
  24. Dearnaley D. P. Cancer of the prostate. BMJ. 1994 Mar 19;308(6931):780–784. doi: 10.1136/bmj.308.6931.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Debruyne F. M., Denis L., Lunglmayer G., Mahler C., Newling D. W., Richards B., Robinson M. R., Smith P. H., Weil E. H., Whelan P. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol. 1988 Oct;140(4):775–777. doi: 10.1016/s0022-5347(17)41809-x. [DOI] [PubMed] [Google Scholar]
  26. Debruyne F. M., Dijkman G. A., Lee D. C., Witjes W. P., del Moral F., Karthaus H. F., van der Mejden A. P., Plasman J. W., Pull H. C., Kums J. J. A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol. 1996 Apr;155(4):1352–1354. [PubMed] [Google Scholar]
  27. Decensi A. U., Boccardo F., Guarneri D., Positano N., Paoletti M. C., Costantini M., Martorana G., Giuliani L. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol. 1991 Aug;146(2):377–381. doi: 10.1016/s0022-5347(17)37799-6. [DOI] [PubMed] [Google Scholar]
  28. Delaere K. P., Van Thillo E. L. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol. 1991 Oct;18(5 Suppl 6):13–18. [PubMed] [Google Scholar]
  29. Denis L. J., Carnelro de Moura J. L., Bono A., Sylvester R., Whelan P., Newling D., Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993 Aug;42(2):119–130. doi: 10.1016/0090-4295(93)90634-m. [DOI] [PubMed] [Google Scholar]
  30. Denis L. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Prostate. 1995 Nov;27(5):233–240. doi: 10.1002/pros.2990270502. [DOI] [PubMed] [Google Scholar]
  31. Denis L. Prostate cancer. Primary hormonal treatment. Cancer. 1993 Feb 1;71(3 Suppl):1050–1058. doi: 10.1002/1097-0142(19930201)71:3+<1050::aid-cncr2820711425>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  32. Dijkman G. A., Debruyne F. M., Fernandez del Moral P., Plasman J. W., Hoefakker J. W., Idema J. G., Sykes M. A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur Urol. 1995;27(1):43–46. doi: 10.1159/000475122. [DOI] [PubMed] [Google Scholar]
  33. Drakos P. E., Gez E., Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer. 1992;28A(11):1931–1932. doi: 10.1016/0959-8049(92)90041-y. [DOI] [PubMed] [Google Scholar]
  34. Dupont A., Gomez J. L., Cusan L., Koutsilieris M., Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol. 1993 Sep;150(3):908–913. doi: 10.1016/s0022-5347(17)35646-x. [DOI] [PubMed] [Google Scholar]
  35. Fernandez del Moral P., Dijkman G. A., Debruyne F. M., Witjes W. P., Kolvenbag G. J. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology. 1996 Dec;48(6):894–900. doi: 10.1016/s0090-4295(96)00300-7. [DOI] [PubMed] [Google Scholar]
  36. Ferrari P., Castagnetti G., Ferrari G., Pollastri C. A., Tavoni F., Dotti A. Combination treatment in M1 prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3880–3885. doi: 10.1002/1097-0142(19931215)72:12+<3880::aid-cncr2820721724>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  37. Fosså S. D., Aass N., Opjordsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol. 1994 Oct;21(5):657–661. [PubMed] [Google Scholar]
  38. Fosså S. D. Quality of life in prostate cancer: what are the issues and how are they measured? Eur Urol. 1996;29 (Suppl 2):121–123. doi: 10.1159/000473852. [DOI] [PubMed] [Google Scholar]
  39. Geller J., Albert J., Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):53–61. [PubMed] [Google Scholar]
  40. Goldenberg S. L., Bruchovsky N., Gleave M. E., Sullivan L. D., Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995 May;45(5):839–845. doi: 10.1016/s0090-4295(99)80092-2. [DOI] [PubMed] [Google Scholar]
  41. Greenberg R. N. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6(5):592–599. [PubMed] [Google Scholar]
  42. Harris M. G., Coleman S. G., Faulds D., Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1993 Jan-Feb;3(1):9–25. doi: 10.2165/00002512-199303010-00002. [DOI] [PubMed] [Google Scholar]
  43. Henriksson P., Edhag O. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Br Med J (Clin Res Ed) 1986 Aug 16;293(6544):413–415. doi: 10.1136/bmj.293.6544.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Iversen P., Christensen M. G., Friis E., Hornbøl P., Hvidt V., Iversen H. G., Klarskov P., Krarup T., Lund F., Mogensen P. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990 Sep 1;66(5 Suppl):1058–1066. doi: 10.1002/cncr.1990.66.s5.1058. [DOI] [PubMed] [Google Scholar]
  45. Iversen P., Rasmussen F., Asmussen C., Christensen I. J., Eickhoff J., Klarskov P., Larsen E., Mogensen P., Mommsen S., Rosenkilde P. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol. 1997 Mar;157(3):929–934. [PubMed] [Google Scholar]
  46. Iversen P., Rasmussen F., Klarskov P., Christensen I. J. Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3851–3854. doi: 10.1002/1097-0142(19931215)72:12+<3851::aid-cncr2820721717>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  47. Janknegt R. A., Abbou C. C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J. M., Da Silva F. C., Chisholm G., Crawford E. D., Debruyne F. M. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993 Jan;149(1):77–83. doi: 10.1016/s0022-5347(17)36003-2. [DOI] [PubMed] [Google Scholar]
  48. Janknegt R. A., Boon T. A., van de Beek C., Grob P. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology. 1997 Mar;49(3):411–420. doi: 10.1016/s0090-4295(96)00496-7. [DOI] [PubMed] [Google Scholar]
  49. Jurincic C. D., Horlbeck R., Klippel K. F. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study. Semin Oncol. 1991 Oct;18(5 Suppl 6):21–25. [PubMed] [Google Scholar]
  50. Kaisary A. V. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur Urol. 1997;31 (Suppl 2):14–27. doi: 10.1159/000474543. [DOI] [PubMed] [Google Scholar]
  51. Kaisary A. V. Compliance with hormonal treatment for prostate cancer. 1996 Mar 20-Apr 2Br J Hosp Med. 55(6):359–366. [PubMed] [Google Scholar]
  52. Kaisary A. V. Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate Suppl. 1994;5:27–33. doi: 10.1002/pros.2990250709. [DOI] [PubMed] [Google Scholar]
  53. Kaisary A. V., Tyrrell C. J., Peeling W. B., Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991 May;67(5):502–508. doi: 10.1111/j.1464-410x.1991.tb15195.x. [DOI] [PubMed] [Google Scholar]
  54. Kaisary A., Klarskov P., McKillop D. Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide). Anticancer Drugs. 1996 Jan;7(1):54–59. doi: 10.1097/00001813-199601000-00006. [DOI] [PubMed] [Google Scholar]
  55. Kelly W. K., Scher H. I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993 Mar;149(3):607–609. doi: 10.1016/s0022-5347(17)36163-3. [DOI] [PubMed] [Google Scholar]
  56. Knönagel H., Bolle J. F., Hering F., Senn E., Hodel T., Neuenschwander H., Biedermann C. Die Therapie des metastasierten Prostatakarzinoms durch Orchiektomie plus Anandron versus Orchiektomie plus Placebo. Erste Ergebnisse einer randomisierten Multizenterstudie. Helv Chir Acta. 1989 Aug;56(3):343–345. [PubMed] [Google Scholar]
  57. Kolvenbag G. J., Blackledge G. R. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996 Jan;47(1A):70–84. doi: 10.1016/s0090-4295(96)80012-4. [DOI] [PubMed] [Google Scholar]
  58. Korman L. B. Treatment of prostate cancer. Clin Pharm. 1989 Jun;8(6):412–424. [PubMed] [Google Scholar]
  59. Kuhn J. M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J. F., Costa P., Husson J. M., Dahan R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989 Aug 17;321(7):413–418. doi: 10.1056/NEJM198908173210701. [DOI] [PubMed] [Google Scholar]
  60. Labrie F., Crawford D. Anti-androgens in treatment of prostate cancer. Lancet. 1995 Oct 14;346(8981):1030–1031. [PubMed] [Google Scholar]
  61. Labrie F., Dupont A., Belanger A. Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol. 1985:193–217. [PubMed] [Google Scholar]
  62. Labrie F., Dupont A., Belanger A., Cusan L., Lacourciere Y., Monfette G., Laberge J. G., Emond J. P., Fazekas A. T., Raynaud J. P. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med. 1982;5(4):267–275. [PubMed] [Google Scholar]
  63. Labrie F., Luthy I., Veilleux R., Simard J., Bélanger A., Dupont A. New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res. 1987;243A:145–172. [PubMed] [Google Scholar]
  64. Lowe F. C., Bamberger M. H. Indications for use of ketoconazole in management of metastatic prostate cancer. Urology. 1990 Dec;36(6):541–545. doi: 10.1016/0090-4295(90)80199-w. [DOI] [PubMed] [Google Scholar]
  65. Lundgren R. Flutamide as primary treatment for metastatic prostatic cancer. Br J Urol. 1987 Feb;59(2):156–158. doi: 10.1111/j.1464-410x.1987.tb04809.x. [DOI] [PubMed] [Google Scholar]
  66. Lundgren R., Nordle O., Josefsson K. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group. J Urol. 1995 May;153(5):1580–1586. [PubMed] [Google Scholar]
  67. Lundgren R., Sundin T., Colleen S., Lindstedt E., Wadström L., Carlsson S., Hellsten S., Pompeius R., Holmquist B., Nilsson T. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Scand J Urol Nephrol. 1986;20(2):101–105. doi: 10.3109/00365598609040556. [DOI] [PubMed] [Google Scholar]
  68. Lunglmayr G. Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group. Anticancer Drugs. 1995 Aug;6(4):508–513. doi: 10.1097/00001813-199508000-00003. [DOI] [PubMed] [Google Scholar]
  69. Lunglmayr G., Girsch E., Meixner E. M., Viehberger G., Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res. 1988;16(4):315–319. doi: 10.1007/BF00263642. [DOI] [PubMed] [Google Scholar]
  70. Namer M., Toubol J., Caty A., Couette J. E., Douchez J., Kerbrat P., Droz J. P. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):909–915. doi: 10.1016/0960-0760(90)90442-n. [DOI] [PubMed] [Google Scholar]
  71. Narayan P., Trachtenberg J., Lepor H., Debruyne F. M., Tewari A., Stone N., Das S., Jimenez-Cruz J. F., Shearer R., Klimberg I. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology. 1996 Apr;47(4):497–504. doi: 10.1016/s0090-4295(99)80484-1. [DOI] [PubMed] [Google Scholar]
  72. Nieh P. T. Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995 Mar;153(3 Pt 2):1070–1073. [PubMed] [Google Scholar]
  73. Ohri S. K., Gaer J. A., Keane P. F. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol. 1991 Feb;67(2):213–213. doi: 10.1111/j.1464-410x.1991.tb15113.x. [DOI] [PubMed] [Google Scholar]
  74. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994 Mar;12(3):608–616. doi: 10.1200/JCO.1994.12.3.608. [DOI] [PubMed] [Google Scholar]
  75. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5–27. doi: 10.3322/canjclin.47.1.5. [DOI] [PubMed] [Google Scholar]
  76. Paulson D. F. Multimodal therapy of prostatic cancer. Urology. 1981 Apr;17(4 Suppl):53–56. [PubMed] [Google Scholar]
  77. Pavone-Macaluso M., de Voogt H. J., Viggiano G., Barasolo E., Lardennois B., de Pauw M., Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol. 1986 Sep;136(3):624–631. doi: 10.1016/s0022-5347(17)44996-2. [DOI] [PubMed] [Google Scholar]
  78. Perry C. M., McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49–74. doi: 10.2165/00002512-199507010-00006. [DOI] [PubMed] [Google Scholar]
  79. Pfitzenmeyer P., Foucher P., Piard F., Coudert B., Braud M. L., Gabez P., Lacroix S., Mabille J. P., Camus P. Nilutamide pneumonitis: a report on eight patients. Thorax. 1992 Aug;47(8):622–627. doi: 10.1136/thx.47.8.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Quartey P. Anti-androgens in treatment of prostate cancer. Lancet. 1995 Oct 14;346(8981):1031–1031. [PubMed] [Google Scholar]
  81. Robinson M. R. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer. 1993 Dec 15;72(12 Suppl):3855–3857. doi: 10.1002/1097-0142(19931215)72:12+<3855::aid-cncr2820721718>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  82. Schellhammer P. F., Sharifi R., Block N. L., Soloway M. S., Venner P. M., Patterson A. L., Sarosdy M. F., Vogelzang N. J., Chen Y., Kolvenbag G. J. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. Cancer. 1996 Nov 15;78(10):2164–2169. doi: 10.1002/(sici)1097-0142(19961115)78:10<2164::aid-cncr18>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  83. Schellhammer P. F., Sharifi R., Block N. L., Soloway M. S., Venner P. M., Patterson A. L., Sarosdy M. F., Vogelzang N. J., Schellenger J. J., Kolvenbag G. J. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology. 1997 Sep;50(3):330–336. doi: 10.1016/s0090-4295(97)00279-3. [DOI] [PubMed] [Google Scholar]
  84. Scher H. I., Kelly W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993 Aug;11(8):1566–1572. doi: 10.1200/JCO.1993.11.8.1566. [DOI] [PubMed] [Google Scholar]
  85. Small E. J., Baron A. D., Fippin L., Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997 Apr;157(4):1204–1207. [PubMed] [Google Scholar]
  86. Small E. J., Baron A., Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997 Nov 1;80(9):1755–1759. doi: 10.1002/(sici)1097-0142(19971101)80:9<1755::aid-cncr9>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  87. Soloway M. S., Schellhammer P., Sharifi R., Venner P., Patterson A. L., Sarosdy M., Vogelzang N., Jones J., Kolvenbag G. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. Eur Urol. 1996;29 (Suppl 2):105–109. doi: 10.1159/000473848. [DOI] [PubMed] [Google Scholar]
  88. Stege R., Carlström K., Hedlund P. O., Pousette A., von Schoultz B., Henriksson P. Intramuskuläres Depotöstrogen (Estradurin) in der Behandlung von Patienten mit Prostatakarzinom. Historische Aspekte, Wirkungsmechanismus, Resultate und aktueller klinischer Stand. Urologe A. 1995 Sep;34(5):398–403. [PubMed] [Google Scholar]
  89. Trachtenberg J. Progress in complete androgen blockade. Eur Urol. 1997;31 (Suppl 2):8–27. doi: 10.1159/000474541. [DOI] [PubMed] [Google Scholar]
  90. Tyrrell C. J., Altwein J. E., Klippel F., Varenhorst E., Lunglmayr G., Boccardo F., Holdaway I. M., Haefliger J. M., Jordaan J. P. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. J Urol. 1991 Nov;146(5):1321–1326. doi: 10.1016/s0022-5347(17)38080-1. [DOI] [PubMed] [Google Scholar]
  91. Tyrrell C. J. Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. Prostate Suppl. 1992;4:97–104. doi: 10.1002/pros.2990210515. [DOI] [PubMed] [Google Scholar]
  92. Watanabe S., Yamasaki S., Tanae A., Hibi I., Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc Committee on Androcur Users. Lancet. 1994 Dec 3;344(8936):1567–1568. doi: 10.1016/s0140-6736(94)90373-5. [DOI] [PubMed] [Google Scholar]
  93. Waxman J., Pandha H. Anti-androgens in treatment of prostate cancer. Lancet. 1995 Oct 14;346(8981):1030–1030. [PubMed] [Google Scholar]
  94. Wingo P. A., Landis S., Ries L. A. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin. 1997 Jul-Aug;47(4):239–242. doi: 10.3322/canjclin.47.4.239. [DOI] [PubMed] [Google Scholar]
  95. Wysowski D. K., Fourcroy J. L. Flutamide hepatotoxicity. J Urol. 1996 Jan;155(1):209–212. [PubMed] [Google Scholar]
  96. Wysowski D. K., Freiman J. P., Tourtelot J. B., Horton M. L., 3rd Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993 Jun 1;118(11):860–864. doi: 10.7326/0003-4819-118-11-199306010-00006. [DOI] [PubMed] [Google Scholar]
  97. da Silva F. C., Fossa S. D., Aaronson N. K., Serbouti S., Denis L., Casselman J., Whelan P., Hetherington J., Fava C., Richards B. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer. 1996 Jan;32A(1):72–77. doi: 10.1016/0959-8049(95)00402-5. [DOI] [PubMed] [Google Scholar]
  98. de Voogt H. J., Klijn J. G., Studer U., Schröder F., Sylvester R., De Pauw M. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):965–969. doi: 10.1016/0960-0760(90)90451-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES